{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-280172","form_type":"8-K","ticker":"ACRV","cik":"0001781174","company_name":"Acrivon Therapeutics, Inc.","filed_at":"2025-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.433630+00:00","generated_at":"2026-05-16T20:29:40.155691+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Acrivon Therapeutics Q3 2025 net loss $18.2M, cash $134.4M to fund into Q2 2027","bullets":["Net loss of $18.2M for Q3 2025, improved from $22.4M in Q3 2024.","Cash, cash equivalents and investments of $134.4M as of Sep 30, 2025; funds operations into Q2 2027.","R&D expenses fell to $13.6M from $18.9M due to fewer milestones and trial prioritization.","Advancing ACR-368 Phase 2b trial for endometrial cancer; initial ACR-2316 Phase 1 data expected H2 2025.","Presented AP3 platform data at AACR-NCI-EORTC; new cell cycle program targets candidate nomination in 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-280172","json":"https://secwatch.observer/filing/0001193125-25-280172.json","markdown":"https://secwatch.observer/filing/0001193125-25-280172.md","text":"https://secwatch.observer/filing/0001193125-25-280172.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1781174/000119312525280172/0001193125-25-280172-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1781174/000119312525280172/acrv-20251113.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T20:29:40.155691+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}